tAAV9-IL-12

tAAV9-IL-12 is an investigational tumor-targeted gene therapy designed to deliver Interleukin-12 (IL-12) specifically to the tumor microenvironment. Developed by Taxell Therapeutics and Cure Genetics, the therapy utilizes a modified adeno-associated virus 9 (AAV9) vector, termed tAAV9, which is conjugated to an anti-folate receptor 1 (anti-FOLR1) antibody fragment (scFv) using Spy-ligation technology. This modification allows the vector to selectively infect FOLR1-positive tumor cells following intravenous administration. Once inside the tumor cells, the vector drives the expression of IL-12, a potent pro-inflammatory cytokine that stimulates anti-tumor immune responses. The targeted delivery approach is intended to maximize therapeutic efficacy while reducing the systemic toxicity and short half-life typically associated with recombinant IL-12 protein therapy. Preclinical studies in ovarian cancer xenograft models have demonstrated significant tumor suppression and a favorable safety profile.